Bone Marrow Cell Transplantation into the Heart is Not a Crucial Factor of Ventricular Fibrillation in a Rat Doxorubicin-Induced Cardiomyopathy Model
To verify the susceptibility of ventricle to arrhythmia after bone marrow mononuclear cell transplantation (BMMNCT), we measured ventricular fibrillation threshold (VFT) and monophasic action potential duration (MAPD<SUB>90</SUB>). Lewis rats with doxorubicin-induced cardiomyopathy were divided into 2 groups: transplantation group (D–TX: BMMNC (1×10<SUP>6</SUP>) given transplants into the apex at 4 weeks after doxorubicin administration) and non-transplantation group (D–N). Age-matched normal group (N–N) was prepared. At 4 weeks after BMMNCT, the following electrophysiologic tests were performed. Experiment 1 (VFT): Two stainless wires were placed at the apex and a single train of 10 square wave stimuli was delivered across T wave. The lowest current developing ventricular fibrillation was determined as VFT. Experiment 2 (MAPD<SUB>90</SUB>): The catheter was inserted into the left ventricle and pressed against the endocardium near the apex under regular cycle lengths. Experiment 1: VFT of D–TX and D–N were significantly lower than that of N–N (p<0.01). There was no difference between D–TX and D–N. Experiment 2: MAPD<SUB>90</SUB> of each group was lined up in length D–N > D–TX > N–N at every cycle lengths. There was a significant difference between D–N and N–N (p<0.01), and D–TX and N–N (p<0.05). In this model, BMMNCT did not increase susceptibility to arrthythmia.
- Journal of arrhythmia
Journal of arrhythmia 22(2), 86-91, 2006-08-25
Japanese Heart Rhythm Society